Shanghai Pharmaceuticals Holding Co., Ltd (FRA:S1R)
Germany flag Germany · Delayed Price · Currency is EUR
1.280
0.00 (0.00%)
At close: Jan 27, 2026

FRA:S1R Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
279,630274,187259,152231,240215,824191,423
Other Revenue
1,0641,0641,143741.24-485.96
280,694275,251260,295231,981215,824191,909
Revenue Growth (YoY)
3.04%5.75%12.21%7.49%12.46%2.86%
Cost of Revenue
251,038244,837229,366201,604187,416165,671
Gross Profit
29,65630,41330,92930,37728,40826,238
Selling, General & Admin
18,19218,32619,52719,17318,37616,797
Research & Development
2,2942,3942,2042,1121,9871,657
Other Operating Expenses
825.26712.38376.86654.72633.18587.25
Operating Expenses
21,73621,66522,34922,21420,94218,956
Operating Income
7,9208,7488,5818,1647,4667,282
Interest Expense
-1,751-1,857-1,885-1,689-1,518-1,412
Interest & Investment Income
3,836902.81461.83971.412,1501,265
Currency Exchange Gain (Loss)
-73.93-73.9311.4121.5110.1-41.43
Other Non Operating Income (Expenses)
-26.38-72.07-109.59-116.44-128.71-119.03
EBT Excluding Unusual Items
9,9067,6487,0597,3517,9796,974
Impairment of Goodwill
-230.47-230.47---19.21-486.27
Gain (Loss) on Sale of Investments
149.36178.43155.93218.74-206116.8
Gain (Loss) on Sale of Assets
202.24187.9792.481,43958.2952.15
Asset Writedown
-942.71-218.05-70.65-322.79-69.77-15.77
Legal Settlements
-26.56-26.56-12.69-37.38-8.1-34.82
Other Unusual Items
616.09480.29-169.95160.13409.61569.14
Pretax Income
9,6748,0207,0548,8088,1447,175
Income Tax Expense
2,8412,1501,8881,8161,8691,570
Earnings From Continuing Operations
6,8335,8705,1676,9926,2755,605
Minority Interest in Earnings
-1,187-1,317-1,399-1,375-1,181-1,109
Net Income
5,6454,5533,7685,6175,0934,496
Net Income to Common
5,6454,5533,7685,6175,0934,496
Net Income Growth
40.24%20.82%-32.92%10.28%13.28%10.17%
Shares Outstanding (Basic)
3,6923,7043,7013,4832,8422,842
Shares Outstanding (Diluted)
3,6923,7043,7013,4832,8422,842
Shares Change (YoY)
-0.93%0.07%6.28%22.54%--
EPS (Basic)
1.531.231.021.611.791.58
EPS (Diluted)
1.531.231.021.611.791.58
EPS Growth
41.56%20.73%-36.77%-10.06%13.29%10.04%
Free Cash Flow
3,2163,4262,2612,058942.553,835
Free Cash Flow Per Share
0.870.930.610.590.331.35
Dividend Per Share
0.4100.3700.4100.6100.4200.480
Dividend Growth
-16.33%-9.76%-32.79%45.24%-12.50%9.09%
Gross Margin
10.56%11.05%11.88%13.10%13.16%13.67%
Operating Margin
2.82%3.18%3.30%3.52%3.46%3.79%
Profit Margin
2.01%1.65%1.45%2.42%2.36%2.34%
Free Cash Flow Margin
1.15%1.24%0.87%0.89%0.44%2.00%
EBITDA
9,45910,27010,0819,6898,9738,779
EBITDA Margin
3.37%3.73%3.87%4.18%4.16%4.57%
D&A For EBITDA
1,5381,5221,5001,5261,5071,496
EBIT
7,9208,7488,5818,1647,4667,282
EBIT Margin
2.82%3.18%3.30%3.52%3.46%3.79%
Effective Tax Rate
29.37%26.81%26.76%20.62%22.95%21.88%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.